BridgeBio Pharma, Inc. Common Stock

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North Ameri...

Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR fra...

BridgeBio Pharma announced a $1 billion preferred equity investment led by Sixth Street ($800M) and HealthCare Royalty ($133.9M). The Series A Cumulative Convertible Preferred Stock features a 7% dividend and conversion price of $137.79 per share (100%+ premium to 30-day VWAP). The capital strengthens BridgeBio's balance sheet as it prepares for ...

The cardiovascular disease market is experiencing significant growth with U.S. heart disease costs projected to quadruple by 2050. The global AI cardiology market is expected to reach $14 billion by 2034, while interventional cardiology devices market will grow from $31.12 billion to $42.39 billion by 2031. Five major companies are advancing card...

BridgeBio announced long-term efficacy data from the ATTRibute-CM trial showing acoramidis (Attruby) achieved a 44.7% reduction in all-cause mortality and 49.3% reduction in cardiovascular mortality at Month 54 compared to placebo. The drug demonstrated sustained clinical benefits including mitigation of NT-proBNP progression and maintained quali...